Showing 7411-7420 of 7755 results for "".
- FDA Clears Scar Management Gel from Oculus and Quinnovahttps://practicaldermatology.com/news/20131204-fda_clears_scar_management_gel_from_oculus_and_quinnova/2459398/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for Microcyn Scar Management HydroGel, for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures, and trauma wounds. Oculus U.S. dermatology partner, Quinnova
- ASLMS Announces Dr. Horace Furumoto Award Recipientshttps://practicaldermatology.com/news/20131126-laser_society_announces_dr_horace_furumoto_award_recipients/2459402/Michael H. Slayton, Ph.D. and Ishan Barman, Ph.D. will receive the Horace Furumoto Innovations Professional Development Awards at the upcoming meeting of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), which will be held in April 2014, in Phoenix, AZ. Dr. Thomas Rohrer, Chair of the
- LEO Pharma Expands QualityCareTM Patient Support Programhttps://practicaldermatology.com/news/20131126-leo_pharma_expands_qualitycaretm_patient_support_program/2459403/LEO Pharma Inc. has expanded its QualityCareTM Program, a free and confidential patient support service for people affected by psoriasis or actinic keratosis. In addition to live nurse support through the www.qualitycarebyleo.com, the website also allows patients to choose relevant topics of interes
- Valeant's Antifungal Agent Luzu Wins FDA Approvalhttps://practicaldermatology.com/news/20131115-valeants_antifungal_luzu_wins_fda_approval/2459414/The FDA has approved Luzu® (luliconazole, Valeant) Cream, 1% for the topical treatment of athlete's foot (interdigital tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and olde
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Data Indicate Need to Critically Assess Sunscreen Formulationshttps://practicaldermatology.com/news/20131107-data_indicate_need_to_critically_assess_sunscreen_formulations/2459419/When it comes to sunscreen selection, consumers may benefit from an assessment of a product's specific formulation rather than simply a “Broad Spectrum” claim, according to a poster presented at last month's Fall Clinical Dermatology Conference (Ouyang, et al.). The poster analyzed the critical wave
- Cosmetic Surgery Forum Announces Innovators in Dermatology Recipientshttps://practicaldermatology.com/news/20131107-cosmetic_surgery_forum_announces_innovators_in_dermatology_recipients/2459420/The upcoming Cosmetic Surgery Forum (www.cosmeticsurgeryforum.com), taking place at the ARIA Resort and Casino in Las Vegas from December 5-7, recently announced the recipients of its “Innovators in Dermatology” presentation. Among those honored this year will be Jim Hartman, Vice President of US Ae
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that
- Onset Dermatologics Acquires Worldwide Rights to Clindagel from Galderma Laboratorieshttps://practicaldermatology.com/news/20131031-onset_dermatologics_acquires_worldwide_rights_to_clindagel_from_galderma_laboratories/2459425/Onset Dermatologics, LLC recently announced the acquisition of Clindagel (clindamycin phosphate gel 1%), a prescription topical antibiotic for the treatment of acne, from Galderma Laboratories. Clindagel is the only FDA-approved topical form
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo